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The mechanisms of how chemotherapeutic drugs lead to cell cycle checkpoint regulation and DNA 
damage repair are well understood, but how such signals are transmitted to the cellular apoptosis 
machinery is less clear. We identified a novel apoptosis-inducing complex, we termed 
FADDosome, which is driven by ATR-dependent caspase-10 upregulation. During FADDosome-
induced apoptosis, cFLIPL is ubiquitinated by TRAF2, leading to its degradation and subsequent 
FADD-dependent caspase-8 activation. Cancer cells lacking caspase-10, TRAF2 or ATR switch 
from this cell-autonomous suicide to a more effective, autocrine/paracrine mode of apoptosis 
initiated by a different complex, the FLIPosome. It leads to processing of cFLIPL to cFLIPp43, TNF-
 production and consequently, contrary to the FADDosome, p53-independent apoptosis. Thus, 
targeting the molecular levers that switch between these mechanisms can increase efficacy of 






Anti-tumour drugs exert their effect by inducing programmed cell death 1. Apoptosis can be 
initiated by various stimuli and factors including growth factor withdrawal, UV, -irradiation, 
signalling by death receptors or chemotherapeutic drugs 2 and has been broadly separated into two 
distinct processes: (a) signal-mediated apoptosis, also known as extrinsic cell death triggered by 
binding of death ligands such as FasL/CD95L or TRAIL to their cognate receptors 3 and (b) cell 
death caused by intracellular stress, as for instance initiated by cytotoxic drugs, also known as the 
intrinsic pathway that typically uses caspase-9 as the initiator caspase 4 5 6. However, there is also 
ample evidence for the existence and function of other initiator caspase activities upstream of 
mitochondria in stress- and drug-induced cell death 7, 8, 9, 10.  
Recently, apoptosis induction mechanisms involving caspase-8 have been discovered in connection 
with compounds that block inhibitor-of-apoptosis-proteins (IAPs). Treatment with such 
compounds resulted in proteasomal degradation of cIAP1, cIAP2 and XIAP leading to NF-κB 
activation, upregulation of TNF-α production and subsequent autocrine TNFR1- and caspase-8-
mediated apoptosis 11, 12, 13, 14, 15. Later, the topoisomerase II inhibitor Etoposide, which gives rise 
to DNA double strand breaks, was shown to cause apoptosis through a seemingly similar 
mechanism in HeLa cells 16. Additionally, it was shown that IAP inhibition either alone or in 
combination with Etoposide gives rise to an apoptosis-inducing, RIP1-dependent complex termed 
RIPoptosome 14, 15. However, Etoposide was previously reported to engage the classic caspase-9-
mediated pathway 17, 18. In view of these controversial data, it appears that aside from the canonical 
caspase-9 pathway several other, possibly cell-type specific, cytotoxic drug-triggered apoptosis-
induction mechanisms exist. Furthermore, it remains elusive how the cellular damage caused by 
these drugs is sensed, and then signalled up to the varying apoptosis pathways and mechanisms. 
The two serine/threonine protein kinases ATR and ATM are key factors involved in the DNA 
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damage response, but there are only a few reports describing how they function in apoptosis 
signalling 19. ATM has been linked to cytokine and caspase signalling upon strong genotoxic 
damage as well as to PIDD phosphorylation required for RAIDD binding and caspase-2 activation 
16, 20
. However, very little is known how these responses vary based on treatment type and 
molecular make-up of cancer cells.  
Given the growing complexity of how different cancer treatments trigger various cell death 
mechanisms, it is important to unravel the cellular and molecular contexts that determine the 
utilisation of the various pathways in cancer cells, and to exploit this new knowledge for diagnostic 





5FU-induced apoptosis is mediated by a caspase-9- and RIPoptosome-independent process 
that is initiated by caspase-8 
In order to reduce the complexity caused by overlapping cell death modi we applied a prescreen to 
identify compounds that act solely through apoptosis mechanisms that have not been previously 
described with the aim of identifying novel pathways (Figure 1a). Through this experimental 
strategy, we found that 5FU induces apoptosis via a potentially novel mechanism (Supplementary 
Figures 1a-e). AnnexinV/PI staining, DNA hypodiploidy assays, caspase Western blots and 
measurements of mitochondrial membrane potential (MMP) of cells treated with 5FU alone or in 
combination with zVAD confirmed that 5FU induces apoptosis and other apoptotic processes in a 
caspase-dependent manner (Figure 1b and Supplementary Figures 2a-d). To test the causal 
involvement of caspase-8 as initiator caspase we knocked-out caspase-8 by CRISPR/Cas9 gene 
editing and found that these cells were resistant to 5FU-induced apoptosis (Figure 1c). Silencing 
of caspase-8 by RNAi confirmed these findings, whereas targeting of caspase-2 and caspase-9 had 
no significant impact on cell death levels (Supplementary Figures 2e-k). In contrast, Etoposide-
induced cell death was not affected by silencing or knock-out of caspase-8 (Supplementary Figures 
2e and 2l). Silencing of cFLIP did not significantly impact on 5FU-induced apoptosis in HCT116 
cells (Supplementary Figure 2m). Additionally, while 5FU showed caspase-8 activity in a 
luciferase-based assay, Etoposide did not (Figure 1d and Supplementary Figure 2n). To validate 
and verify caspase-8 as the proximal caspase in 5FU-induced apoptosis, we carried out a molecular 
trapping assay using a biotinylated caspase inhibitor (bVAD). For 5FU treated HCT116 cells this 
assay revealed caspase-8 as the initiator caspase, whereas caspase-9 and caspase-2 could not be 
detected (Figure 1e). While not all drugs acted via this pathway, e.g. Etoposide, others also required 
the presence of caspase-8 such as Raltitrexed or the topoisomerase I inhibitor Irinotecan 
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(Supplementary Figure 2o). To test the impact of caspase-8 on clonogenicity and relevance in 5FU 
responses in vivo, we carried out colony forming assays (CFAs) and established xenografts. The 
CFAs revealed that silencing of caspase-8 allowed substantial survival and outgrowth, in contrast 
to controls (Supplementary Figure 2p). Similar results were obtained in the xenograft study (Figure 
1f and Supplementary Figure 2q).  
 
Caspase-8 activation is p53- and death receptor-independent 
Next, we analysed whether 5FU-induced caspase-8 activation was p53 dependent 21. We compared 
p53-proficient HCT116 and HCTp53-/- cells for caspase-8 activity following 5FU treatment. 
Despite lower apoptosis levels in the p53-null cells (Figure 2a), caspase-8 activation was 
unchanged in these cells as compared to their isogenic parental cells (Figure 2b). The importance 
of caspase-8 even in the p53-null context was underscored by the fact that apoptosis, albeit at 
overall low levels, was significantly reduced by silencing of caspase-8 (Figure 2c). As 
mitochondrial depolarisation in response to 5FU was lower in HCTp53-/- than in HCT116 cells 
(Figure 2d) it appears that the signal from activated caspase-8 onto mitochondria was attenuated in 
the p53-negative cells resulting in diminished caspase-3 activation. Activated caspase-8 signals to 
mitochondria via the BH3-only protein Bid. When we silenced Bid in HCT116 cells (HCT.shBid), 
we found significantly decreased apoptosis and mitochondrial depolarisation after treatment with 
5FU, but no reduction in caspase-8 activity (Figures 2e and 2f and Supplementary Figure 3a). Thus, 
Bid is an essential signalling intermediate in 5FU-induced apoptosis, necessary for mitochondrial 
activation. As we demonstrated that caspase-9 is not required, we hypothesised that not cytochrome 
c, but other factors, Smac/DIABLO in particular, are important to overcome XIAP-enforced 
inhibition of executioner caspase activation. We therefore, silenced XIAP in HCT.shBid cells, 
mimicking the release of Smac/DIABLO, and treated with 5FU. Such cells showed restored 
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apoptosis and caspase-3 activation to almost parental HCT116 levels (Figure 2g and 
Supplementary Figure 3b). Similarly, when we knocked down XIAP in p53-silenced cells we 
observed the same increase in apoptosis (Figure 2h). Thus, p53 is involved in the execution of 5FU-
induced apoptosis via engagement of mitochondria, but not needed for the initiation of cell death 
at the level of caspase-8 activation.  
 
Caspase-10 is upregulated in response to 5FU in a p53-independent manner and forms a 
complex with FADD and caspase-8  
In order to elucidate the underlying mechanism of caspase-8 activation in response to 5FU, we 
carried out an RNA-Seq analysis. From 568 genes that were significantly upregulated 
(Supplementary Table 1), five were potential caspase-8 binding partners and also upregulated as 
proteins (Figures 3a and 3b and Supplementary Table 2). Of these, CD95, TRAIL-R1 
(TNFRSF10A) and TRAIL-R2 (TNFRSF10B) are p53-target genes and were therefore not good 
candidates as drivers for 5FU-induced, p53-independent caspase-8 activation. Furthermore, 
blocking these receptors with neutralising antibodies caused no change in apoptosis levels 
(Supplementary Figure 4a). As Caspase-10 and cIAP2 upregulations were p53-independent (Figure 
3c), we tested their capacity to induce apoptosis in HCT116 cells as compared to HCT.shC8 cells. 
Forced expression of caspase-10 but not cIAP2 gave rise to caspase-8-driven apoptosis implicating 
caspase-10 in the formation of the caspase-8 activation complex (Figure 3d and Supplementary 
Figure 4b). Indeed, when we immunoprecipitated caspase-8 from 5FU-treated HCT116 cells we 
could detect coprecipitation of processed caspase-10 and the adaptor protein FADD, but not cIAP2 
or the death receptors (Figure 3e and Supplementary Figure 4c). These results were confirmed in 
caspase-10 overexpressing cells, i.e. after immunoprecipitation with caspase-8 antibodies, we were 
able to detect caspase-10 and FADD (Figure 3f). Furthermore, when we pulled-down 
 8 
overexpressed tagged versions of FADD in 5FU-treated 293 cells we were able to co-precipitate 
caspase-8 and caspase-10, and could also demonstrate FADD multimerisation in these cells 
(Supplementary Figure 4d).  Thus, an induced complex containing FADD, caspase-10, and 
caspase-8 appeared to be responsible for the activation of caspase-8 and apoptosis induction. The 
formation of such a complex was corroborated by a sucrose gradient analysis that showed a shift 
of caspase-8, FADD and caspase-10 to higher molecular weight fractions (~2 MDa) after 5FU 
treatment (Supplementary Figure 4e). This shift of FADD and caspase-10 was absent in HCT.shC8 
cells, but not in HCT.shBid cells, demonstrating the specificity of the analysis (Supplementary 
Figure 4f). To further elucidate the role of FADD and caspase-10, we generated respective knock-
down cell lines (Supplementary Figure 4g). Silencing of FADD in HCT116 and HT-29 cells 
resulted in inhibition of both 5FU-induced apoptosis and caspase-8 activation (Figures 3g and 3h), 
as well as a lack of a shift of caspase-8 and caspase-10 in sucrose gradient analyses (Supplementary 
Figure 4h). On the other side knocking down of caspase-10 surprisingly led to significantly 
increased levels of cell death, which could still be blocked by the caspase inhibitor zVAD (Figure 
3i and Supplementary Figure 4i). Thus, apoptosis in HCT.shC10 cells is a caspase-dependent 
process similar to HCT116 cells, but the markedly higher levels pointed to a potentially different 
and distinct mechanism in these cells. 
 
Lack of Caspase-10 leads to TNF- production in response to 5FU and FADD-independent 
apoptosis  
Studying HCT.shC10 cells in more detail revealed, that similar to HCT116 cells, 5FU led to 
caspase-8 activation and caspase-8-dependent cell death, but silencing of FADD in HCT.shC10 
cells did not result in apoptosis resistance (Figure 4a). The FADD-independency was confirmed 
by a lack of FADD multimerisation in HCT.shC10 cells in response to 5FU and a lack of a shift of 
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FADD in sucrose gradient analyses (Supplementary Figure 5a). These results indicate that caspase-
10 deficiency indeed leads to a switch to a different apoptosis mechanism. Next, we examined 
whether death receptors/death ligands were behind 5FU-induced caspase-8 activation and 
apoptosis in caspase-10 knock-down cells. While both FasL and TRAIL-blocking antibodies did 
not affect cell death levels, antibodies directed against TNF- and its receptor TNFR1 significantly 
decreased apoptosis (Figure 4b and Supplementary Figure 5b). As this was not the case in HCT116 
cells (Supplementary Figure 5b), we concluded that in HCT.shC10 cells 5FU triggered the 
production of TNF-, which in turn gave rise to apoptosis. An ELISA of supernatants from 
HCT.shC10 cells confirmed the TNF-generation (Figure 4c). In addition, we discovered that 
IB- was phosphorylated and degraded in HCT.shC10, but not in control cells indicating that 
5FU-induced NF-B activation gave rise to TNF- upregulation (Figure 4d). Blocking NF-κB 
activation by overexpression of IκB-SR in HCT.shC10 cells stopped the 5FU-induced TNF-α 
production and inhibited apoptosis (Figure 4e and Supplementary Figure 5c). Cell death and TNF-
 generation could also be blocked by silencing of caspase-8 in HCT.shC10 cells demonstrating 
that caspase-8 was not only required for the TNF--induced apoptosis, but was also crucial for the 
production of the cytokine in the first place (Figure 4f). Having excluded FADD as a functional 
partner in caspase-8 activation in HCT.shC10 cells, we turned to another known caspase-8 binding 
partner, cFLIP. We discovered that cFLIPL was degraded in HCT116 cells following 5FU 
treatment, but in HCT.shC10 cells the cFLIPL levels hardly changed, and instead a cleaved form 
of cFLIPL, cFLIPp43, appeared (Figure 4g). A more detailed analysis revealed that cleavage of 
cFLIPL to cFLIPp43 is required for TNF- production, as both cFLIPL and cFLIPp43, but not the 
cleavage-mutant cFLIPD376N, were capable of turning on TNF- generation after 5-FU treatment 
(Figure 4h). In contrast, silencing of cFLIP in HCT.shC10 cells gave rise to significantly reduced 
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TNF- production in response to 5FU (Figure 4i). When we overexpressed cFLIPL and cFLIPp43 
in caspase-8 silenced cells we found that neither of the two was able to induce TNF- production 
demonstrating that caspase-8 activity was not only needed to cleave cFLIPL, but also required as a 
platform to facilitate NF-B activation (Figure 4j). As for the prominent role of cFLIP in the 
complex triggering TNF-α production, we termed this complex FLIPosome consisting of caspase-
8 and cFLIPL (Figure 4k), whereas the caspase-8 activation complex in HCT116 cells was named 
FADDosome in recognition of the central role of FADD therein. In order to examine the utility of 
switching tumour cells to drug-induced TNF-α production as a sensitisation approach, we used 
HCT.shC10 cells in an in vivo study. We found that HCT.shC10 xenografts responded significantly 
better to 5FU than control xenografts (Figure 4l and Supplementary Figures 5d and 5e).  
 
TRAF2 is recruited to the FADDosome by caspase-10 and RIP1 and is responsible for cFLIPL 
ubiquitination and degradation  
TNF- production and its involvement in apoptosis has been described in the context of other 
apoptosis inducing mechanisms e.g. the action of IAP inhibitors or TNF- feedforward signalling. 
We were therefore interested whether these cell death mechanisms and complexes are comparable 
to the FLIPosome. Another key feature of these pathways and also the RIPoptosome is the 
degradation of IAPs, and indeed cIAP1 was degraded in response to 5FU in caspase-10 silenced 
cells (Figure 5a). RIP1 has been described as a core and essential component of the mentioned 
apoptosis mechanisms. However, when we measured apoptosis in HCT.shC10.shRIP1 double 
knock-down cells, we did not observe diminished cell death, ruling out a role for RIP1 and the 
RIPoptosome (Figure 5b). Interestingly, we discovered that in single RIP1 knock-down cells 
(HCT.shRIP1) apoptosis was higher than in HCT.shctrl cells closely resembling HCT.shC10 cells 
(Figure 5b and Supplementary Figure 6a). Again, both cIAP1 and IB- were degraded in 
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HCT.shRIP1 cells and TNF- was produced in response to 5FU, which could be inhibited by IB-
SR expression (Figure 5c and Supplementary Figure 6b). Hence, while RIP1 is not a critical factor 
for apoptosis, it is an essential factor for FADDosome formation, and RIP1 deficiency instead leads 
to the FLIPosome.  
As we showed that proteolytic degradation of cFLIPL is a hallmark of the FADDosome, we set out 
next to identify the E3 ubiquitin ligase activity that binds within the FADDosome and initiates the 
proteolytic pathway. We analysed three candidate proteins, TRAF2, cIAP1 and cIAP2, which 
possess ubiquitin ligase activity and are known to be principally able to interact with FADDosome 
constituents. Co-IPs revealed that in addition to FADD and caspase-10, RIP1 and TRAF2 were 
bound to caspase-8 after 5-FU treatment (Figure 5d). This finding was strengthened by the fact that 
caspase-8 activity could be precipitated with RIP1 (Supplementary Figure 6c). When we knocked 
down TRAF2 in HCT116 cells (HCT.shTRAF2) we detected, similarly to HCT.shC10 and 
HCT.shRIP1 cells, higher apoptosis levels in response to 5FU and TNF- production that could be 
blocked by IB-SR (Figure 5e and Supplementary Figures 6d and 6e). Thus, the FADDosome was 
expanded by two additional factors, RIP1 and TRAF2. Furthermore, when we overexpressed 
TRAF2 we saw ubiquitination of cFLIPL, which was absent in cells overexpressing a TRAF2-
RING variant lacking ubiquitin ligase activity as well as in cells overexpressing cIAP1 or cIAP2 
(Figure 5f and Supplementary Figure 6f). Similarly, we found cFLIPL degradation in 5FU-
stimulated control HCT116 cells expressing either EGFP or TRAF2, but not in the TRAF2-RING 
sample, which, acting in a dominant-negative manner, blocks cFLIPL degradation (Figure 5g). 
These results demonstrate that TRAF2 is likely to be the ubiquitin ligase that is recruited to the 
FADDosome where it mediates cFLIP ubiquitination and degradation. In addition, RIP1 and 
caspase-10 are required for the TRAF2 recruitment and subsequent molecular processes and 
absence of any of the three factors leads to apoptosis through FLIPosome action instead. 
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ATR is essential for caspase-10 upregulation and FADDosome formation 
Finally, we wondered how the cellular damage inflicted by cytotoxic drugs is translated into 
apoptosis signals inside the treated cells. Most chemotherapeutic drugs cause DNA damage, with 
5FU additionally being able to give rise to perturbation in RNA metabolism. DNA damage 
activates the ATM and ATR kinases via autocatalytic phosphorylation. Once activated, they 
phosphorylate a plethora of proteins that control and repair DNA damage, but only very few direct 
molecular links to apoptosis induction have been established. When we checked for ATM and ATR 
activation in response to 5FU, we found only ATR to be phosphorylated, whereas with Etoposide 
we obtained reverse results, i.e. only ATM was phosphorylated (Figure 6a and Supplementary 
Figure 7a). Thus, we silenced ATR in HCT116 cells (HCT.shATR) (Supplementary Figure 7b) and 
also used the ATR inhibitor AZD6738 in combination with 5FU. When we measured apoptosis in 
these cells we discovered that both ATR silencing and AZD6738 caused significantly increased 
apoptosis (Figure 6b). An ELISA of the supernatants of 5FU-stimulated HCT.shATR cells, as well 
as ATR inhibitor co-treated cells, detected TNF- production, resembling the situation in 
HCT.shC10 cells. It appeared that cells lacking ATR activity engaged the FLIPosome to initiate 
apoptosis (Figure 6c). A subsequent Western blot analysis revealed that caspase-10 was no longer 
upregulated in cells with knocked-down or blocked ATR (Figure 6d). Furthermore, blocking ATR 
led to inhibition of Chk1 phosphorylation and p53 activation in response to 5FU (Figure 6d). 
Furthermore, we found the FLIPsome to act in a p53-independent manner (Supplementary Figures 
7c-e) and that a specific Thymidylate Synthase (TS) inhibitor (Raltitrexed) could only give rise to 
FADDosome-mediated apoptosis, but was unable to trigger TNF- production (Supplementary 
Figures 7f-h). These findings reveal a novel ATR-caspase-10 axis and also provide new insights 





Despite the evident importance of treatment-induced cell death induction in cancer cells, 
knowledge of the molecular steps that initiate and progress the apoptotic signalling cascade remain 
sketchy. However, a detailed understanding of the molecular event(s) leading to apoptosis is crucial 
for the development of improved diagnostic and predictive tools as well as novel therapeutic 
approaches.  
We found that drugs that are known to give rise to replication stress and consequent single-strand 
DNA breaks lead to caspase-8 initiated apoptosis. These findings are in contrast to the consensus 
view that caspase-9 initiates the apoptosis cascade in response to cytotoxic drugs and other 
intracellular stressors 22, 23. The observed caspase-8 activation was independent of death-receptor 
triggering, in contrast to what was shown in the past for other cytotoxic drugs in different cancer 
cells 24, 25. As RIP1 was also not essential for apoptosis, ruling out the RIPoptosome or TNF- 
feedforward signalling, we concluded that a novel caspase-8 mechanism must be responsible, for 
which our results suggest the following model (Figure 7). In response to treatment, ATR detects 
the drug-produced DNA lesions and elicits upstream signals that are responsible for the p53-
independent caspase-10 upregulation. This provides the germ for the subsequent formation of the 
FADDosome, which aside from caspase-10, contains FADD, caspase-8, RIP1 and TRAF2 (Figure 
7a). Within the FADDosome, cFLIPL is ubiquitinated by TRAF2 leading to its degradation. 
Interestingly, in the TRAIL DISC it is not cFLIPL but its sibling molecule caspase-8 that is 
ubiquitinated by TRAF2 pointing to context-specific activities and effects 26. Caspase-8, FADD, 
caspase-10, TRAF2 and also RIP1 as well as ATR are all required for FADDosome formation, 
with the latter four factors being dispensable for apoptosis. In the absence of these factors, cells 
switch to an alternative mechanism that involves a complex we termed FLIPosome and caspase-8-
mediated cleavage of cFLIPL to cFLIPp43 comparable to findings in the CD95 DISC 27, 28 (Figure 
 15 
7b). This results in NF-B activation that drives expression of TNF- causing apoptosis in an 
autocrine and paracrine fashion. FLIPosome-induced apoptosis is, in contrast to the FADDosome, 
FADD- and p53-independent, providing distinct therapeutic advantages in solid tumours 
harbouring dysfunctional p53. The fact that both FADD as well as RIP1 are dispensable for the 
FLIPosome distinguishes it also from the RIPoptosome as well as the TNF-α feedforward 
signalling pathway 14, 16. Our results demonstrate that the FLIPosome is the more efficacious 
apoptosis mechanism as also evident by the increased 5FU responsiveness in xenografts derived 
from caspase-10 silenced cells. Thus, flicking the switch from cell autonomous apoptosis to non-
autonomous cell death via the TNF--pathway provides a potential new avenue to overcome 
resistance in tumour cells and/or increase treatment efficacy. The latter type of apoptosis, also 
known as “communal death” normally plays a role in tightly regulated developmental processes, 
which require a coordinated cell death response 29. It is a conserved mechanism found in flies and 
mammals that has also been implicated in the synchronous apoptosis wave observed in certain 
pathologies such as cardiac infarction and alcohol-/drug-induced liver failure 30, 31, 32. Our results 
indicate that tumour cells have either maintained or are able to reactivate this archaic pathway that 
it is controlled by caspase-10. Our results regarding a regulatory but not directly apoptotic activity 
of caspase-10 are not dissimilar to findings about its role in the CD95 and TRAIL DISCs 33 
indicating a general role in orchestrating caspase-8 activation and cellular fate. Importantly, the 
caspase-10 gene has been shown to be lost in mice 34, 35. As they are commonly used in the study 
of cancer treatments including apoptosis pathways, caution should be exercised when transferring 
results obtained in murine rodents to the human setting. 
Our results also indicate a novel mode of action of ATR inhibitors when used in combination with 
other treatments as has been widely proposed. Owing to blocked DNA repair, such cells appear to 
respond with the more fulminate FLIPosome/TNF--mediated cell death type including systemic 
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anti-tumour functions of the immune system. These approaches also have the added advantage to 
be effective in p53-null cells. Having delineated the described apoptosis mechanisms and pathways 
offers several targets to interfere with and to engage at least one of the two different routes to 
apoptosis in order to bypass resistance points in cancer cells.   
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Methods 
Reagents. All chemicals, unless otherwise stated, were purchased from Sigma. Pancaspase 
inhibitor zVAD.fmk (zVAD) was from Santa Cruz Biotechnology and biotinylated-VAD.fmk 
(bVAD) was bought from Calbiochem. Recombinant CD95L was purchased from Enzo Life 
Sciences. Recombinant TRAIL was purchased from R&D Systems. Recombinant TNF- was 
purchased from Peprotech. The ATR inhibitor AZD6738, Raltitrexed and Irinotecan were bought 
from Stratech. 
Antibodies. Sheep anti-CuZnSOD (The Binding Site), goat and mouse anti-actin (Santa Cruz 
Biotechnology), rabbit anti-TRAIL-R2 (Cell Signaling Technology), mouse anti-caspase-3 
(Imgenex), mouse anti-caspase-8 (Cell Signaling Technology, Santa Cruz Biotechnology  and BD 
Biosciences), mouse anti-XIAP (BD Biosciences), mouse-anti-cFLIP (AdipoGen), goat anti-cIAP1 
(R&D Systems), rat anti-cIAP2 (Enzo Life Sciences), mouse anti-caspase-9 (Novus Biologicals), 
mouse anti-caspase-2 (BD Biosciences), mouse anti-CD178 (BD Biosciences), mouse anti-TNFR1 
(Santa Cruz Biotechnology), rabbit anti-TRAIL (Peprotech), rabbit anti-TRAIL-R1 (Santa Cruz 
Biotechnology), mouse anti-TNFR1 (Hycult Biotech), mouse anti-FADD (Millipore), rabbit anti-
Bid (R&D Systems), mouse anti-RIP1 (BD Biosciences), mouse anti-p53 (BD Biosciences), mouse 
anti-caspase-10 (MBL), rabbit anti-CD95 (Santa Cruz Biotechnology), mouse anti-TRAF2 (Santa 
Cruz Biotechnology), rabbit anti-TRADD (Cell Signaling Technology), rabbit anti-
CRADD/RAIDD (Cell Signaling Technology), rabbit anti-NEMO (Santa Cruz Biotechnology), 
mouse anti-Myc (Santa Cruz Biotechnology), mouse anti-V5 (Thermo Fisher Scientific), rabbit 
anti-IκB-α (Cell Signaling Technology), rabbit anti-Phospho-IκB-α (Cell Signaling Technology), 
rabbit anti-Phospho-ATR (GeneTex), rabbit  anti-ATR (Bethyl Laboratories), rabbit anti-Phospho-
ATM (Cell Signaling Technology), mouse anti-ATM (Sigma), rabbit anti-Phospho-Chk1 (Cell 
Signaling Technology), mouse anti-Chk1 (Cell Signaling Technology), mouse anti-TNF-α 
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(Biolegend), IgG1 Isotype antibody (BD Biosciences), IgG2a Isotype antibody (Biolegend), IgG2b 
Isotype antibody (Biolegend), mouse anti-Smac/DIABLO antibody (Abcam), FITC-conjugated 
F(ab‘)2 anti-mouse IgG2a antibody (Southern Biotechnology), FITC-conjugated F(ab‘)2 anti-
mouse IgG2b antibody (Southern Biotechnology), mouse anti-cytochrome c (BD Biosciences). 
Peroxidase-conjugated secondary antibodies were anti-mouse, anti-rabbit, anti-goat, anti-rat and 
anti-sheep (Santa Cruz Biotechnology). For co-immunoprecipitations TrueBlot peroxidase-
conjugated secondary antibodies were used (Rockland). 
Cell lines. Human colorectal tumour HCT116 cells (ATCC), their isogenic daughter cell line 
HCTp53-/- (gift from Bert Vogelstein) and HT-29 (ATCC) cells were grown in McCoy’s (Lonza) 
supplemented with 10% FBS (Life Technologies), 100 U/ml penicillin and 100 g/ml 
streptomycin. Human ovarian cancer cell line A2780 (Sigma) was grown in RPMI-1640 medium 
supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin. Human cervix 
carcinoma HeLa cells (ATCC) and human breast carcinoma MDA-MB-231 cells (ATCC) were 
grown in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml 
penicillin and 100 g/ml streptomycin. 
Overexpression constructs. Flag-cIAP2/pRK5 was a gift from Xiaolu Yang (Addgene plasmid # 
27973) 36, pcdna3.1 hciap1 was a gift from Jon Ashwell (Addgene plasmid # 8311) 37. HA-
Ubiquitin was a gift from Edward Yeh (Addgene plasmid # 18712) 38. Caspase-10 was purchased 
from Invivogen. TRAF2, pCMV6.FADD.MYC and cFLIP were bought from Origene. Generation 
of cFLIP constructs: cFLIPL was cloned into pcDNA3.1/V5-His TOPO-TA (Life Technologies). 
cFLIPp43 was generated by PCR and cloned into pcDNA3.1/V5-His TOPO-TA (Life 
Technologies). The 3’-PCR primer contains a stop codon, so that the V5-His tag is not expressed. 
FLIPD376N was generated by site-directed mutagenesis of the cFLIPL construct using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). Generation of TRAF2 
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constructs: TRAF2 Ring was generated by PCR and along full-length TRAF2 cloned into 
pcDNA3.1. Generation of FADD constructs: To obtain two differently tagged FADD constructs, 
FADD was also cloned into pcDNA3.1/V5-His TOPO-TA (Life Technologies) by PCR. The 
resulting construct was termed pcDNA.FADD.V5. Generated constructs were validated by 
sequencing. 
Knock-down constructs and stable cell line generation. The following small hairpin (sh) RNA 
motifs were used to target XIAP (shXIAP) 39, caspase-8 (shC8) 40, caspase-2 (shC2) (5’-
GACAGCTGTTGTTGAGCGAA-3’), caspase-10 (shC10) (5’-
GCATTGACTCAGAGAACTTAA-3’), Bid (shBid) 40, FADD (shFADD) (5’-
GTGCAGCATTTAACGTCAT-3‘), RIP1 (shRIP) (5’-GCTGCTAAGTACCAAGCTATC-3‘), 
cFLIP (shFLIP) 41, TRAF2 (shTRAF2) 42, p53 (shp53) 43, caspase-9 (shC9) 44, EGFP (shEGFP) 44, 
ATR (shATR) 45, scrambled (shsc)  (5’- GCGTAAGTCGCACGTCACACA-3’), Lamin A/C 
(shLamin) (Life Technologies). Sense and antisense oligos containing the short-hairpin sequence 
were hybridised to generate double-stranded DNA fragments. These fragments were then cloned 
into a modified pU6.ENTR plasmid (Life Technologies). The resulting pU6.ENTR plasmids were 
used to generate the pAd.sh plasmids using the LR Clonase II system (Life Technologies). 
Furthermore, the pU6.ENTR plasmids were used to generate the pBlockiT.sh plasmids (Life 
Technologies) to generate stable knock-downs. For this, the respective pBlockiT.sh plasmids were 
FuGene HD transfected into cells. Three days later, the transfected cells were split into Blasticidin 
containing selection medium. Arising clones were picked, transferred to 24-well plates and tested 
for gene silencing. Moreover, shLamin clones, which were generated by transfection with the 
pBlockiT6-GW/U6-lamin.shRNA plasmid, served as RNAi controls (Figure S7b and S7b). To 
generate the shC10/shFADD, shC10/shRIP1, shC10/shC8 and shC10/shp53 double knock-down 
clones, we generated shFADD, shRIP1, shC8 and shp53 RNAi plasmids in psiRNA-h7SKzeo 
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(InvivoGen). For this, we ligated the double-stranded DNA fragment, containing the respective 
motifs into the BbsI- (Bpi1; Fisher Scientific) opened psiRNA-h7SKzeo vector. The resulting 
plasmids were FuGene HD transfected into HCT.shC10 cells. Following the same procedure as 
described above, the cells were selected in Zeocin (InvivoGen) containing medium.  A clone 
generated with empty plasmids served as HCT.shctrl cells. 
Generation of knock-out cell lines via CRISPR/Cas9. Sequences of gRNAs were selected 
according to the Zhang lab. The respective gRNAs were inserted into the pX459 V2.0 plasmid as 
previously described 46. HCT116 cells were transfected with the respective pX459 V2.0 gRNA 
plasmid. 24 h post transfection, positive cells were selected using puromycin prior to clonal 
expansion in normal growth medium. After 3-4 weeks, clones were screened for knock-out by 
immunoblot. 
Generation of adenoviral vectors and transduction. Adenoviral vectors expressing cFLIPL 
(Ad.cFLIPL) and dominant negative caspase-9 (Ad.DN-C9) were purchased from Vector Biolabs. 
IκB-SR (Ad.IκBSR), DsRed (Ad.DsRed) and enhanced green fluorescent protein (EGFP; 
Ad.EGFP) were described previously 39, 47, 48. Adenoviral vectors encoding small hairpin constructs 
were generated using the ViraPower adenoviral expression system (Life Technologies).  
Adenoviral vectors encoding small hairpin constructs were targeted against EGFP, cFLIP, caspase-
8, caspase-2, caspase-9, XIAP, and p53 genes, respectively. The vectors were named Ad.shEGFP, 
Ad.shcFLIP, Ad.shC8, Ad.shC2, Ad.shC9, Ad.shXIAP and Ad.shp53. A vector expressing a 
scrambled shRNA (Ad.shsc) served as additional control. For adenoviral transduction, the normal 
growth medium was changed to medium with 2% FBS. The cells were transduced with virus at 
200 pfu/cell for 6 hours and then washed off.  
Apoptosis measurements. To determine drug induced cell death, cells were stimulated with 200 
µM 5FU (48 h), 50 µM Raltitrexed (72 h), 10 µM Irinotecan (48 h) or 100 µM etoposide (48 h), 
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respectively. The pancaspase inhibitor zVAD was used at 20 µM and incubated for 4 h as pre-
treatment before 5FU was added. DNA-hypodiploidy staining: Cells including their medium 
supernatant and PBS wash were harvested and centrifuged at 1,300 rpm for 7 min at 4o C. After 
washing with PBS, Nicoletti  buffer (Sodium citrate 0.1 % (w/v) containing 0.1 % Triton X-100 
(w/v) and propidium iodide 50 µg/ml) 49 was added to the cell pellets, tubes were vortexed for 10 
s at medium speed and left for 5 h in the dark (4o C). The fluorescence intensity was then measured 
in a flow cytometer and analysed with the Venturi One software package (Applied Cytometry). 
Normally, absolute apoptosis levels are depicted, but when specific apoptosis is shown, it was 
determined by subtraction of the basal apoptosis values from the cell death levels of treated cells. 
AnnexinV/PI staining. The AnnexinV/PI staining was carried out as follows: Cells were treated 
with 5FU and harvested 48 h later. Cells were then trypsinised and spun down at 1,300 rpm for 7 
min at 4ºC. Subsequently, cells were washed with binding buffer (10 mM HEPES NaOH [pH 7.4], 
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) and recentrifuged. The cell pellets were 
resuspended in binding buffer containing AnnexinV (Roche) at a final concentration of 2.5 μg/ml 
and incubated for 15 min at 4º C in the dark. Shortly before the measurement, PI solution was 
added at a final concentration of 2 μg/ml in binding buffer prior to analysis.  
Necrosis measurement. Loss of plasma membrane integrity: Cells were harvested and washed in 
PBS, centrifuged at 1,300 rpm for 5 minutes, and then resuspended in 100 μl PBS. Shortly before 
FACS measurement, PI (to 2 μg/ml) was added. 
Clonogenic assay. HCT.shctrl and HCTshC8 cells were treated with 200 M 5FU for 15 h before 
10,000 cells were seeded in normal growth medium. After three weeks resulting colonies were 
fixed in 2% paraformaldehyde (PFA) and visualised with a 0.04% crystal violet solution. Colonies 
were then counted. 
 22 
Neutralising antibody and death ligand treatments. Cells were pretreated with the following 
antibodies: anti-CD178 (NOK1) (25 µg/ml), anti-TRAIL (0.5 µg/ml) and anti-TNF-α (10 µg/ml) 
for 5 h, followed by 5FU stimulation for 48 h. The efficacy of the antibodies was tested by 
stimulating with their respective ligands. In this context, cells were pretreated as described above, 
before addition of the respective death-ligands. CD95L was used at a concentration of 250 ng/ml 
and TRAIL at a concentration of 5 ng/ml for 48 h. Cells were pre-treated with anti-TNFR1 antibody 
(Hycult Biotech) (100 µg/ml) for 24 h, followed by 5FU and anti-TNFR1 cotreatment.  
Measurement of the mitochondrial membrane potential. Perturbations in mitochondrial 
transmembrane potential were monitored by ﬂow cytometry. Cells were treated with 200 µM 5FU 
for 24 h, or left untreated as control. Following drug treatment, cells were harvested and washed 
with prewarmed PBS. The cells were then labelled with 2 nM DIOC6(3) (Thermo Fisher Scientific) 
at 37° C for 20 min and subsequently analysed by FACS. 
Cytochrome c measurements. HCT116 cells were either pretreated with 20 µM zVAD for 4 h or 
left untreated before 5FU was added for 48 h. FACS analysis of cytochrome c release was 
performed according to a previously described protocol 50. Cytochrome c release is detected as a 
drop in the fluorescent signal. 
Smac/DIABLO release. HCT116 cells were either pretreated with 20 µM zVAD for 4 h or left 
untreated before 5FU was added for 48 h, harvested and prefixed with 0.01% PFA for 20 min at 4° 
C. Prefixation was followed by an additional fixation step with 0.12% PFA for 20 min before the 
cells were permeabilised with 0.1% Saponin for 5 min at 4° C.  Next, mouse IgG1 was added (50 
μg/ml) for 20 min at 4° C, followed by 1 µg/ml anti-Smac/DIABLO antibody for an additional 20 
min at 4° C. IgG2a isotype antibody was used as control. For Smac/DIABLO staining, the cells 
were incubated with FITC-conjugated goat F(ab‘)2 anti-mouse IgG2a antibody (1:20) for 20 min 
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at 4° C in the dark. Samples were then analysed by FACS. Smac/DIABLO release is detected as 
an increase in the fluorescent signal. 
Western blot. Proteins were separated by SDS-PAGE and transferred onto PVDF membranes (GE 
Healthcare Biosciences). Primary and secondary antibodies were diluted in TBS, 0.1% Tween and 
3% BSA. Bands were visualised with ECL Western blotting substrate (Thermo Fisher Scientific). 
CuZnSOD served as loading control. 
TNF- Enzyme-Linked Immunosorbent Assay (ELISA). To examine TNF-α levels, we plated 
1x107 cells in a 15 cm dish. We transduced or transfected the cells 24 h before 5FU stimulation. 
Cells were stimulated with 100 µM 5FU for 24 h before medium was exchanged to zVAD (20 µM) 
containing serum-free medium (UltraCULTURE, Lonza). After 72 h cell culture supernatants were 
cleared and concentrated 5-fold. For concentrating of supernatants we used Amicon Ultra-
centrifugal Filters (3 kDa). A commercial TNF-α ELISA Kit (R&D Systems) was used following 
the manufacturer’s instructions.  
Cytokine Array. For these studies, we took blood from two mice of each treatment group at the 
end of each experiment and separated serum from whole blood. The respective sera were diluted 
1:5 and applied to mouse cytokine antibody arrays III (RayBio) according to manufacturer’s 
instructions. We normalised each cytokine signal to its internal control and compared each 
treatment group (PBS treated HCT.shctrl animals with PBS treated HCT.shC10 animals [PBS] and 
5FU treated HCT.shctrl animals with 5FU treated HCT.shC10 animals [5FU]) with each other and 
expressed changes in caspase-10 silenced xenografts in different colours. We used a two colour 
scale from green (1.5 fold change) to red (5 fold change).  
Sucrose density gradient fractionation. The sucrose gradient protocol was adapted from Feig et 
al. 51. Briefly, cells were treated with 5FU for 24 h before they were harvested, washed once with 
ice-cold PBS and resuspended in 1% Triton X-100 buffer (30 mM Tris-HCl [pH 7.5]; 150 mM 
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NaCl; 2.5 mM EDTA; 10% (v/v) glycerol; 1% (v/v) Triton X-100; Protease inhibitors). Cell lysis 
was carried out for 10 min on ice and lysates were cleared of debris by centrifugation at 14,000 
rpm for 10 min at 4° C. The protein lysate (1.5 mg) was overlaid on top of the sucrose gradient (10 
- 50% (w/w) sucrose), which was then subjected to ultracentrifugation at 37,500 rpm for 16 h. 14 
equal fractions were then collected and subjected to SDS-PAGE and Western blotting for proteins 
of interest.  
Immunoprecipitation experiments. Cells were plated overnight and stimulated with 5FU for 24 
h unless otherwise indicated. Cells were collected, washed in ice-cold PBS, and lysed in the 
appropriate immunoprecipitation buffer containing protease inhibitor cocktail tablets (Roche). For 
the caspase-8 immunoprecipitation, cells were lysed in NP-40 buffer (50 mM Tris [pH 7.4]; 10% 
glycerol; 0.5% NP40; 150 mM NaCl; 1mM MgCl2; 1 mM CaCl2; 1 mM KCl; Protease inhibitors). 
The caspase-8 antibody (Santa Cruz Biotechnology) was used at a concentration of 1 μg/mg protein 
and cross-linked to Protein A/G agarose (Pierce Crosslink IP Kit, Thermo Fisher Scientific). For 
the Myc-tag immunoprecipitation, cells were plated overnight and followed by co-transfection with 
pCMV6.FADD.MYC and pcDNA.FADD.V5 expression plasmids at equal amounts of DNA. 5 h 
post-transfection, the medium was changed and after an additional 5 h, cells were stimulated with 
5FU for 15 h. Cells were treated with Etoposide (150 μM) 12 h after the change of medium for 
another 15 h. Untreated transfected cells served as controls. Cells were lysed in RIPA buffer 
(50mM Tris-HCl [pH 7.4]; 150mM NaCl; 2mM EDTA; 1% NP-40; 0.1% SDS; Protease 
inhibitors). The Myc antibody was used at a concentration of 1 μg/mg protein and captured with 
magnetic beads pre-coated with anti-mouse antibodies. 
For the RIP1, caspase-8 and actin immunoprecipitations used in the caspase-8 activity assays, cells 
were lysed in NP-40 buffer. The antibodies were used at a concentration of 1 μg/mg protein and 
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captured with Protein A/G agarose (caspase-8 and actin IP) or magnetic beads pre-coated with anti-
mouse antibodies (RIP1 and actin IP).  
Caspase-8 activity assay. Caspase-8 activity was measured after caspase-8, actin and RIP1 
immunoprecipitations, respectively. The caspase-8 and RIP1 immunoprecipitations were 
performed as described above with one additional wash with cold aqua bidest included after the 
magnetic beads were washed 5 times with lysis buffer. Finally, the beads were resuspended in 100 
l aqua bidest followed by addition of 100 l of Caspase-8 Glo buffer (Promega). Luminescent 
readings were carried out and samples were analysed after 1 h. 
In-situ trapping and streptavidin-precipitation of biotinylated initiator caspases. This method 
was performed according to a previously described protocol 52. Cells were pretreated with 50 M 
bVAD for 2 h in their normal growth medium and under normal culture conditions before 5FU was 
added. After 5FU stimulation (18 h), cells were harvested and protein lysates prepared as described 
previously 7. These protein lysates were subsequently mixed with streptavidin-conjugated magnetic 
beads (Thermo Fisher Scientific) and incubated for 16 h. The beads were then washed six times 
with lysis buffer before they were resuspended in Laemmli loading buffer.  
Ubiquitination analysis. HCT116 cells were transfected with 2 µg of the pcDNA.cFLIPL 
expression vector, 2 µg of the pcDNA.HA-Ubiquitin plasmid and 2 µg of either the cIAP1, cIAP2 
or TRAF2 expression constructs. 24 h after the transfection, MG132 (10 µM) was added to the 
cells. 4 h later, the cells were lysed under denaturing conditions with hot lysis buffer (95° C) 
containing 1% SDS, 1 mM EDTA and 50 nM NaF. The lysates were then diluted (1:5) with cell 
lysis buffer. Cleared, diluted lysates were analysed on a 6% SDS-PAGE/Western blot for cFLIP 
ubiquitination. 
Animal studies. Ten weeks old female CD1 nu/nu mice (Harlan) were injected with 5x106 cells in 
200 µl PBS. After ten days and when tumours were palpable the animals were intraperitoneally 
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injected with 5FU (150 mg/kg) once a week over 4 weeks. The growth of the tumours was followed 
over 45 days. The tumour volume was calculated using three different diameters and the formula: 
π/6*(d1*d2*d3). The animal studies were performed according to national laws and were covered 
by a license. 
Histological analyses. Tumour samples taken during necropsy were fixed in 10% neutral-buffered 
formalin, paraffin embedded and 4-μm sections were stained with hematoxylin and eosin (H&E).  
RNA isolation and RNA-Seq. Cells were treated with 5FU for 24 h. Total RNA was isolated using 
TRIZOL (Life Technologies). cDNA library preparation and sequencing was performed on an 
Illumina HiSeq™ 2500 by GATC Biotech. Sequence data quality control was evaluated using the 
FastQC program on the Galaxy platform (http://galaxyproject.org/). Reads were aligned to the 
UCSC hg19 human reference genome using Tophat2. Cufflinks was used to reconstruct the 
transcriptome and differentially expressed genes were identified with Cuffdiff. All analyses were 
performed using the Galaxy platform. Genes that were found to be upregulated in response to 24 h 
5FU treatment were compared to predicted functional partners of caspase-8 (Supplementary File 
S8).  
Statistical analysis. Experimental values are expressed as mean value ± standard error (SEM). For 
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Figure 1. 5FU-induced apoptosis is mediated by a caspase-9- and RIPoptosome-independent 
process that is initiated by caspase-8.  
a. Experimental strategy to identify compounds that act solely through potentially novel apoptosis 
mechanisms.  
b. (Top) AnnexinV/PI staining of HCT116 cells treated with 5FU. (Lower) Caspase-dependent 
apoptosis induction was assessed using zVAD in connection with DNA hypodiploidy assay. 
Representative results are shown.  
c.  (Left) Western blot against caspase-8 with lysates from HCT116 and C8 KO cells. (Right) 
Apoptosis was measured in response to 5FU in these cells. Data are plotted as mean ± SEM 
(n=3). 
d. Caspase-8 activity was measured after 5FU treatment in HCT116 cells. Activity is expressed 
as fold-caspase-8 activation. Immunoprecipitations (IP) with a control antibody (Actin IP) 
served as specificity control. Data are plotted as mean ± SEM (n≥ 
e. Western blots of agarose-streptavidin precipitates from 5FU/bVAD-treated cells were probed 
with caspase-8, -9 and -2 antibodies.  
f. Xenografts from HCT.shC8 and HCT.shctrl cells were treated with 5FU. End point tumour 
volumes are depicted in relation to starting volumes (set to 100) [animal numbers/group: 
n=6/shctrl, n=3/shC8].  
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Figure 2. Caspase-8 activation is p53- and death receptor-independent. 
a. HCT116 and HCTp53-/- (p53-/-) cells were treated with 5FU for 24, 48 and 72 h before 
apoptosis was measured. Data are plotted as mean ± SEM (n≥ 
b. Caspase-8 activity following 5FU treatment was measured in HCT116 and p53-/- cells. Data 
are plotted as mean ± SEM (n= 
c. Caspase-8 was silenced in p53-/- cells (shC8) and apoptosis measured 72 h post-treatment. 
Control knock-down cells (shctrl) were used for comparison. Data are plotted as mean ± SEM 
(n= 
d. MMP measurements in HCT116 and p53-/- cells before (-) and after (+) 5FU treatment. Data 
are plotted as mean ± SEM (n= 
e. Apoptosis and changes in MMP after 5FU treatment were measured in stable Bid-silenced 
HCT116 cells (shBid). Data are plotted as mean ± SEM (n= 
f. Caspase-8 activity following 5FU treatment was measured in HCT.shBid cells. Data are plotted 
as mean ± SEM (n= 
g. XIAP was silenced (Ad.shXIAP) in HCT.shctrl and HCT.shBid cells and apoptosis measured 
after 5FU treatment. Data are plotted as mean ± SEM (n=Controls were shEGFP 
(Ad.shEGFP) double knock-downs. 
h. HCT116 cells were silenced for p53 and XIAP (Ad.shp53 and Ad.shXIAP) and apoptosis 
measured following 5FU treatment. Ad.shEGFP and Ad.shsc served as double knock-down 
control. Data are plotted as mean ± SEM (n≥ 
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Figure 3. Caspase-10 is upregulated in response to 5FU and is part of a FADD and caspase-
8 containing complex.  
a. Venn diagram of genes upregulated by 5FU and a group of predicted caspase-8-interacting 
factors resulting in a union containing five genes.  
b. Western blot for the identified factors after 5FU treatment.  
c. p53-/- cells were treated with 5FU and analysed for caspase-10 and cIAP2 by Western blot at 
the indicated time points.  
d. Apoptosis levels following overexpression of caspase-10 and cIAP2 in HCT.shctrl cells, and 
in addition of caspase-10 in HCT.shC8 cells. EGFP overexpression was used as control. Data 
are plotted as mean ± SEM (n≥  
e. Caspase-8 IP from HCT116 cells treated with 5FU. Complex formation was assessed by 
probing the caspase-8 precipitates for the presence of FADD and caspase-10 by Western blot. 
The panel on the left shows the input controls.  
f. Caspase-8 IP from HCT116 cells overexpressing caspase-10. Complex formation was assessed 
by probing the caspase-8 precipitates for the presence of FADD and caspase-10 by Western 
blot. Input controls are on the left.  
g. FADD was knocked down in HCT116 and HT-29 cells (shFADD) and apoptosis was measured. 
HT-29.shFADD cells were treated with 200 M and 400 M 5FU. Data are plotted as mean ± 
SEM (n= 
h. Caspase-8 activity following 5FU treatment was measured in HCT.shFADD cells. Data are 
plotted as mean ± SEM (n= 
i. Caspase-10 silenced HCT116 cells (shC10) were treated with 5FU and analysed for apoptosis. 
Data are plotted as mean ± SEM (n= 
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Figure 4. Lack of Caspase-10 leads to TNF- production in response to 5FU and FADD-
independent apoptosis.  
a. (Left) Caspase-8 activity was measured in response to 5FU in HCT.shC10 cells. (Right) Double 
knock-down clones, HCT.shC10.shctrl, HCT.shC10.shC8 and HCT.shC10.shFADD were 
tested for apoptosis in response to 5FU. Data are plotted as mean ± SEM (n≥ 
b. 5FU-induced apoptosis was measured in HCT.shC10 cells in the presence of TNF- and TNF-
R1 blocking antibodies. IgG1 and IgG2a antibodies were used as isotype controls, respectively. 
Data are plotted as mean ± SEM (n≥ 
c. TNF- was measured in supernatants of 5FU-treated HCT.shC10 cells. Data are plotted as 
mean ± SEM (n= 
d. HCT.shC10 cells after 5FU treatment were analysed by Western blot for IB- and phospho-
IB-.  
e. HCT.shC10 cells expressing IκB-SR (Ad.IBSR) were treated with 5FU, after which TNF- 
and apoptosis were measured. Ad.EGFP served as control. Data are plotted as mean ± SEM 
(n≥  
f. HCT116 cells silenced for both caspase-10 and caspase-8 were treated with 5FU and TNF- 
was measured. Data are plotted as mean ± SEM (n≥ 
g. Western blot for cFLIP in HCT116 and HCT.shC10 cells after 5FU treatment.  
h. EGFP, cFLIPS, cFLIPL, cFLIPp43 and cFLIPD376N were expressed in HCT116 cells, and then 
the cells treated with 5FU before TNF- levels were measured. Data are plotted as mean ± 
SEM (n≥ 
i. HCT.shC10 cells were silenced for cFLIP (Ad.shFLIP). TNF- in cell culture supernatants was 
then determined after 5FU stimulation. Data are plotted as mean ± SEM (n= 
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j. Either cFLIPL or cFLIPp43 were expressed in HCT.shC8 cells. After 5FU treatment, TNF- was 
measured. Data are plotted as mean ± SEM (n≥ 
k. Precipitates from a caspase-8 IP were probed for cFLIP, FADD and caspase-8. The lysates 
were from HCT116 cells overexpressing cFLIPL and treated with 5FU. Cells overexpressing 
EGFP were used as controls. Input controls are shown on the left.  
l. End point tumour volumes of HCT.shC10 xenografts treated with 5FU are depicted in relation 




Figure 5. RIP1 and TRAF2 are dispensable for 5FU-induced apoptosis, but required for 
FADDosome formation.  
a. Western blot of protein lysates of HCT.shC10 cells, treated with 5FU, probed with cIAP1 
antibodies.  
b. Apoptosis measurements after 5FU treatment of the following stable knock-down clones: 
HCT.shctrl, HCT.shRIP1, HCT.shC10, HCT.sC10.shctrl and HCT.shC10.shRIP1. Data are 
plotted as mean ± SEM (n≥  
c. (Left) HCT.shctrl, HCT.shC10 and HCT.shRIP1 cells were treated with 5FU and the resulting 
protein lysates immuno-blotted and probed with IB- and cIAP1 antibodies. (Right) TNF- 
was measured in HCT.shRIP1 cells treated with 5FU. Data are plotted as mean ± SEM (n≥ 
d. Caspase-8 IP in 5FU-treated HCT116 cells. Resulting precipitates were analysed by Western 
blot for RIP1, TRAF2 and caspase-8. Input controls are shown on the left.  
e. (Left) Apoptosis measurements in HCT.shTRAF2 cells following 5FU treatment. (Right) TNF-
 levels were measured in HCT.shTRAF2 cells treated with 5FU. Data are plotted as mean ± 
SEM (n≥ 
f. EGFP, RING-TRAF2 and TRAF2 were overexpressed in HCT116 cells and 24 h later the 
resulting protein extracts tested by Western blot for cFLIP.  
g. Degradation of cFLIP was analysed in cells overexpressing EGFP, RING-TRAF2 or TRAF2 




Figure 6. ATR is essential for caspase-10 upregulation and FADDosome formation.  
a. Western blot analysing ATR and ATM phosphorylation in HCT116 cells treated with 5FU for 
8 h.  
b. Apoptosis measurements in HCT116 cells treated with 5FU and a 5FU/ATR inhibitor 
combination, as well as HCT.shATR cells treated with 5FU. Data are plotted as mean ± SEM 
(n≥ 
c. TNF- measurements in HCT116 cells treated with 5FU and a 5FU/ATR inhibitor 
combination, as well as HCT.shATR cells treated with 5FU. Untreated HCT.shATR (u) are 
shown as controls.  Data are plotted as mean ± SEM (n≥ 
d. Western blots for caspase-10, phosphorylated Chk1, Chk1 and p53 in HCT116 cells treated 





Figure 7. Model of cancer cell fate decisions following treatment.  
a. Cell-autonomous cell death (FADDosome) as triggered by DNA single-strand breaks denoted 
by the ‘red star’.  
b. Communal cell death (FLIPosome) activated by incorporation of 5FU nucleotides into 
DNA/RNA or other damage types/repair mechanisms (symbolised by green DNA part). 
 
 







